Dry Eye Syndrome Treatment Market : Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Dry Eye Syndrome Treatment Market by treatment type (Lubricant Eye Drops, Anti-inflammatory Drugs, Autologous Serum Eye Drops, Nutrition supplements), disease type (Evaporative dry eye syndrome, Aqueous dry eye syndrome), distribution channel (Hospital pharmacies, Retail pharmacies, Online pharmacies, Others) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Dry Eye Syndrome Treatment Market Size was valued at USD 5.87 billion in 2021 and expected to reach a value of USD  10.81 billion by 2028, growing at a CAGR of 9.11% during the forecast period 2022-2028. Dry eye syndrome (keratoconjunctivitis sicca), is an ocular disease caused by the lack of tear fluid to lubricate the eyes, which leads to problems in vision, tear film instability, and discomfort causes potential damage to the ocular surface. Dry eye syndrome can also cause due to other ocular surface diseases such as ocular allergy and meibomian gland dysfunction. The ocular surface contains 7 components including lacrimal and accessory lacrimal apparatus. Any abnormalities in one of the ocular surface components may cause the dry eye syndrome. Dry eye syndrome is classified into two types namely, evaporative dry eye and pure aqueous deficiency dry eye. The common symptoms associated with dry eye syndrome include ocular irritation, hyperaemia, mucoid discharge, blurred vision, excessive tearing, ocular dryness, photophobia, and grittiness. Dry eye syndrome is measured by a thin strip of filter paper placed at the edge of the eye, called a Schirmer test to measure the amount of tears present in the eye. Global dry eye syndrome treatment market is in the developing stage owing to increase in the research and development activities by the competitors in the dry eye syndrome treatment market. The patents of various dry eye syndrome treatment drugs are in expiry stage, so various pharmaceutical companies are actively involved in the R&D of new drugs. Some of the key strategies followed by various pharmaceutical companies to increase revenue share in global dry eye syndrome treatment market including acquisitions & mergers, collaborations, and launching of new products. For instance, in July 2013, Novaliq GmbH won European approval for its lubricating, drug-delivering eye drop NovaTears, designed for over-the-counter treatment of dry eye syndrome. Similarly, in June 2015,  Allergan plc, a pharmaceutical company acquired Oculeve Inc, a medical device company that focuses on new technologies for dry eye disease to improve market position in the dry eye syndrome treatment market. In addition, in January 2017, Novaliq announced the positive top-line results of phase 2 clinical trial evaluating CyclASol in adults with moderate to severe dry eye disease.

Dry Eye Syndrome Treatment Market

MARKET SUMMARY
-
9.11%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 9.11%
  • Largest Market– Europe
  • Fastest Growing Market–  North America

Dry Eye Syndrome Treatment Market

  • The report on global dry eye syndrome treatment market gives historical, current and future market sizes (US$ Mn) on the basis of by treatment type, disease type, distribution channel and geography.
  • The dry eye syndrome treatment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Nicox (France)
  • Allergan (U.S.)
  • Auven Therapeutics (U.S.)
  • Novartis AG (Switzerland)
  • AFT Pharmaceuticals (New Zealand)
Dry Eye Syndrome Treatment Market Dynamics

The global dry eye syndrome treatment market is expected to grow at a significant CAGR due to rise in the geriatric population (tear glands weaken due to aging and can’t produce sufficient tear fluid to maintain a lubricating film over the eyes) and increase in the prevalence of dry eye syndrome. The increase in the prevalence of diabetes, vitamin A deficiency, lupus, thyroid disorders, and rheumatoid arthritis might fuel the dry eye syndrome treatment market. Moreover, increasing awareness among the population about diagnosis and treatment of dry eye syndrome, steady government support for medical research has allowed researchers to treat this condition more precisely and comprehensively, external stimuli such as laser eye surgery, and computer screen overuse are key factors also boosting the dry eye syndrome treatment market over the forecast period. However, expiration of blockbuster drug patents, the popularity of self-medication by patients is the major restraints for the dry eye syndrome treatment market over the forecast period.


North-America Got Significant Share

Dry Eye Syndrome Treatment Market

Geographically, the dry eye syndrome treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the dry eye syndrome treatment market due to high prevalence of lifestyle disorders which increase the chances of contracting dry eye syndrome, increase in the using medications such as antihistamines, pain relievers and antidepressants also increase the risk of dry eye syndrome in North America. Europe holds a dominant share in dry eye syndrome treatment market attributed to increase in the healthcare infrastructure, rise in the R&D activities, and increase in the usage of various medications which reduce the volume of tears produced in the eyes results in dry eye syndrome. Asia-Pacific is an emerging region in dry eye syndrome treatment market owing to increase in population majorly in India and China, strong government support in Asia-Pacific region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share and forecast from 2022-2028
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Segmentation

Dry Eye Syndrome Treatment Market


Location

GEOGRAPHY

Frequently Asked Questions

The dry eye syndrome treatment market is projected to expand at a CAGR of 9.11% during the forecast period

Nicox (France), Allergan (U.S.), Auven Therapeutics (U.S.), Novartis AG (Switzerland), AFT Pharmaceuticals (New Zealand)

North America is the fastest-growing region for dry eye syndrome treatment market


Report

Table Of Content


Report

Company Profile

  • Novartis AG (Switzerland)
  • Nicox (France)
  • Allergan (U.S.)
  • Santen Pharmaceutical Co., Ltd. (Japan)
  • Otsuka Holdings Co., Ltd. (Japan)
  • Auven Therapeutics (U.S.)
  • AFT Pharmaceuticals (New Zealand)
  • I-Med Pharma, Inc. (Canada)
  • Sun Pharmaceuticals Industries Ltd. (India)
  • Mimetogen Pharmaceuticals (U.S.)
  • Novaliq GMBH (Germany)

Description

Dry Eye Syndrome Treatment Market Size was valued at USD 5.87 billion in 2021 and expected to reach a value of USD  10.81 billion by 2028, growing at a CAGR of 9.11% during the forecast period 2022-2028. Dry eye syndrome (keratoconjunctivitis sicca), is an ocular disease caused by the lack of tear fluid to lubricate the eyes, which leads to problems in vision, tear film instability, and discomfort causes potential damage to the ocular surface. Dry eye syndrome can also cause due to other ocular surface diseases such as ocular allergy and meibomian gland dysfunction. The ocular surface contains 7 components including lacrimal and accessory lacrimal apparatus. Any abnormalities in one of the ocular surface components may cause the dry eye syndrome. Dry eye syndrome is classified into two types namely, evaporative dry eye and pure aqueous deficiency dry eye. The common symptoms associated with dry eye syndrome include ocular irritation, hyperaemia, mucoid discharge, blurred vision, excessive tearing, ocular dryness, photophobia, and grittiness. Dry eye syndrome is measured by a thin strip of filter paper placed at the edge of the eye, called a Schirmer test to measure the amount of tears present in the eye. Global dry eye syndrome treatment market is in the developing stage owing to increase in the research and development activities by the competitors in the dry eye syndrome treatment market. The patents of various dry eye syndrome treatment drugs are in expiry stage, so various pharmaceutical companies are actively involved in the R&D of new drugs. Some of the key strategies followed by various pharmaceutical companies to increase revenue share in global dry eye syndrome treatment market including acquisitions & mergers, collaborations, and launching of new products. For instance, in July 2013, Novaliq GmbH won European approval for its lubricating, drug-delivering eye drop NovaTears, designed for over-the-counter treatment of dry eye syndrome. Similarly, in June 2015,  Allergan plc, a pharmaceutical company acquired Oculeve Inc, a medical device company that focuses on new technologies for dry eye disease to improve market position in the dry eye syndrome treatment market. In addition, in January 2017, Novaliq announced the positive top-line results of phase 2 clinical trial evaluating CyclASol in adults with moderate to severe dry eye disease.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX